Company intelligence / Profile preview

Gordian Stone

San Francisco, California, United Statesprweb.com ↗

Ownership: Private
Development stage: Other

Overview

Gordian Biotechnology has developed a high-throughput in vivo screening platform that enables simultaneous testing of hundreds of gene therapies or targets in animal models highly representative of human disease. Their osteoarthritis program advanced dozens of hits into human ex vivo validation studies with an 80% match to screen predictions. In metabolic-associated steatohepatitis, their pooled library recapitulated 13 out of 16 known clinical outcomes. No programs have reached clinical trials yet.

Therapeutic areas: Metabolic DisordersRheumatologyOther
Modalities: Gene therapyAAV-based gene therapy (Adeno-associated virus)Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Gordian Stone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gordian Stone.

Explore the full profile